Loading…
Joe Fiandra Access to Home Infusion Act of 2023
Legislative Progress
Introduced
September 12, 2023
Latest Action
December 17, 2024
Primary Sponsor
Brian K. FitzpatrickRepublican(PA)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
95pct
462d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (6)
2024 · third_quarter · Medicare/Medicaid
Referred to the Subcommittee on Health.
Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
Committee Consideration and Mark-up Session Held
Committee Consideration and Mark-up Session Held
Forwarded by Subcommittee to Full Committee in the Nature of a Substitute (Amended) by Voice Vote.
Subcommittee Consideration and Mark-up Session Held
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
HR 5397 the Joe Fiandra Access to Home Infusion Act, HR 5526 Seniors' Access to Critical Medications Act; HR 8816 American Medical Innovation and Investment Act; Issues related to patient access to rare disease therapies
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Medicare/Medicaid
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act; AINS to H.R. 8816; AINS to H.R. 5526)
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Medicare/Medicaid
Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act, and issues related to value-based payment arrangements. Issues related to Medicaid Drug Rebate Program. H.R. 5397, Joe Fiandra Access to Home Infusion Act of 2023. Issues concerning cybersecurity. H.R. 10445, Furthering Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025, as it relates to access to home infusion and pharmacy benefit management reforms. H.R. 10545, The American Relief Act of 2025.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Medicare/Medicaid
HR 5397 the Joe Fiandra Access to Home Infusion Act, HR 5526 Seniors' Access to Critical Medications Act; HR 8816 American Medical Innovation and Investment Act; HR 10545 American Relief Act of 2025; Issues related to patient access to rare disease therapies
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Medicare/Medicaid
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act; AINS to H.R. 8816; AINS to H.R. 5526); H.R.10545 - American Relief Act, 2025
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Medicare/Medicaid
Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to access and coverage in Medicare program. Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
Funding and related issue pertaining to improving diagnostics of PI; H.R. 5397, the Joe Fiandra Access to Home Infusion Act.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2024 · fourth_quarter · Health Issues
Funding and related issue pertaining to improving diagnostics of PI; H.R. 5397, the Joe Fiandra Access to Home Infusion Act.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2024 · third_quarter · Health Issues
Funding and related issue pertaining to improving diagnostics of PI; FDA proposal to regulate Laboratory Developed Tests (LDTs); H.R. 5397, the Joe Fiandra Access to Home Infusion Act.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2024 · third_quarter · Medicare/Medicaid
HR 5397 the Joe Fiandra Access to Home Infusion Act, HR 5526 Seniors' Access to Critical Medications Act; HR 8816 American Medical Innovation and Investment Act; Issues related to patient access to rare disease therapies
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Medicare/Medicaid
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act; AINS to H.R. 8816; AINS to H.R. 5526)
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Medicare/Medicaid
Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn) Provisions related to home infusion in H.R.8816 - American Medical Innovation and Investment Act of 2024 (Rep. Buchanan), and H.R. 7623 - Telehealth Modernization Act of 2024 Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to access and coverage in Medicare program. Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Medicare/Medicaid
Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act, and issues related to value-based payment arrangements. Issues related to Medicaid Drug Rebate Program. H.R. 5397, Joe Fiandra Access to Home Infusion Act of 2023. Issues concerning cybersecurity.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
HR 5397 - Joe Fiandra Access to Home Infusion Act HR 5539 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act
Client expense: $330,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Medicare/Medicaid
HR 5397 the Joe Fiandra Access to Home Infusion Act, HR 5526 Seniors' Access to Critical Medications Act; HR 8816 American Medical Innovation and Investment Act; Issues related to patient access to rare disease therapies
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
S 1375 - HELP Copays Act HR 5397 - Joe Fiandra Access to Home Infusion Act HR 5539 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act
Client expense: $370,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Medicare/Medicaid
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act; AINS to H.R. 8816; AINS to H.R. 5526); H.R. 5539, ORPHAN Cures Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
Funding and related issue pertaining to primary immunodeficiency disease; FDA proposal to regulate Laboratory Developed Tests (LDTs); H.R. 5397, the Joe Fiandra Access to Home Infusion Act.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2024 · second_quarter · Medicare/Medicaid
Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act, and issues related to value-based payment arrangements. Issues related to Medicaid Drug Rebate Program. H.R. 5397, Joe Fiandra Access to Home Infusion Act of 2023. Issues concerning cybersecurity.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Medicare/Medicaid
Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn) Provisions related to home infusion in H.R.8816 - American Medical Innovation and Investment Act of 2024 (Rep. Buchanan) Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to access and coverage in Medicare program. Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Medicare/Medicaid
Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn) Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 H.R. 5539, S.3131 - ORPHAN Cures Act Issues related to access and coverage in Medicare program. Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Medicare/Medicaid
HR 5397 the Joe Fiandra Access to Home Infusion Act, Issues related to patient access to rare disease therapies, HR 2882 Further Consolidated Appropriations Act of 2024, HR 4366 the Consolidated Appropriations Act of 2024
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Medicare/Medicaid
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act); H.R. 5539, ORPHAN Cures Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 830 - HELP Copays Act H.R. 5397 - Joe Fiandra Access to Home Infusion Act H.R.5539 - ORPHAN Cures Act S. 1375 - HELP Copays Act S. 3131 - ORPHAN Cures Act
Client expense: $170,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Medicare/Medicaid
Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act, and issues related to value-based payment arrangements. Issues related to Medicaid Drug Rebate Program. H.R. 5397, Joe Fiandra Access to Home Infusion Act of 2023. Issues concerning cybersecurity.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Medicare/Medicaid
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act; HR 6363 Further Continuing Appropriations and other Extensions Act of 2024
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Medicare/Medicaid
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act; HR 6363 Further Continuing Appropriations and other Extensions Act of 2024
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Medicare/Medicaid
H.R. 5397, Joe Fiandra Access to Home Infusion Act of 2023, issues related to Medicare coverage of home infusion; issues related to the implementation of the Inflation Reduction Act; H.R. 5539/S.3131, ORPHAN Cures Act; S. 476/H.R. 5547, Maintaining Investments in New Innovation Act
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Medicare/Medicaid
Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn) Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 H.R. 5539 - ORPHAN Cures Act H.R.2880 - Protecting Patients Against PBM Abuses Act Issues related to access and coverage in Medicare program. Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 830 - HELP Copays Act H.R. 5397 - Joe Fiandra Access to Home Infusion Act S. 1375 - HELP Copays Act 340B Drug Pricing Program PBM Reforms
Client expense: $400,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Medicare/Medicaid
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act); H.R. 5539, ORPHAN Cures Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Medicare/Medicaid
Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act, and issues related to value-based payment arrangements. Issues related to Medicaid Drug Rebate Program. H.R. 5397, Joe Fiandra Access to Home Infusion Act of 2023.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Medicare/Medicaid
Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn) Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to access and coverage in Medicare program. Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Medicare/Medicaid
Improve access to home infusion services; HR 5397 the Joe Fiandra Access to Home Infusion Act
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Medicare/Medicaid
H.R. 5397, Joe Fiandra Access to Home Infusion Act of 2023, issues related to Medicare coverage of home infusion; issues related to the implementation of the Inflation Reduction Act; H.R. 5539, ORPHAN Cures Act; S. 476/H.R. 5547, Maintaining Investments in New Innovation Act
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Medicare/Medicaid
RNA interference scientific advancements; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 830 - HELP Copays Act H.R. 2630 - Safe Step Act H.R. 2666 - MVP Act H.R. 2673 - American Innovation and R&D Competitiveness Act H.R. 3503 - Clinical Trial Diversity Act H.R. 5397 - Joe Fiandra Access to Home Infusion Act S. 652 - Safe Step Act S. 866 - American Innovation and R&D Competitiveness Act S. 1375 - HELP Copays Act Inflation Reduction Act
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| House |
| Referred To |
| September 12, 2023 |
| Democratic |
| FL |
| Dean Phillips | Democratic | MN |
| Earl L. "Buddy" Carter | Republican | GA |
| Josh Harder | Democratic | CA |
| Kevin Hern | Republican | OK |
| Mike Carey | Republican | OH |
| Mike Kelly | Republican | PA |
| Neal P. Dunn | Republican | FL |
| Terri A. Sewell | Democratic | AL |